Growing Market Presence Chroma is expanding its brand recognition through participation in high-profile industry events like the 37th Annual Roth Conference, indicating opportunities to promote services to a well-engaged scientific and health-focused audience.
Financial Performance The company has demonstrated strong revenue growth and profitability driven by NAD+ related products, suggesting a clientele that values advanced health and longevity solutions, ideal for targeting with new innovative product offerings.
Strategic Renaming Rebranding to Niagen Bioscience aligns the company with the NAD+ and healthy aging segment, highlighting potential sales opportunities in biotech, supplement, and health markets focused on longevity and anti-aging sectors.
Technological Leaning Chroma's focus on science-backed NAD+ products and its emphasis on precision science indicates openings for advanced technology and scientific tool providers to collaborate or offer complementary solutions.
Market Trends With a rising global longevity boom and increasing consumer interest in health optimization, there is a clear sales opportunity to engage the company for products or services aligned with health, wellness, and biotech innovation.
$1B$10B
$10B
$250M$500M
$1B$10B
$250M$500M
$250M$500M
$1B$10B
$1B$10B
$1B$10B
$10B| Chroma Email Formats | Percentage |
| First.Last@chromasports.com | 50% |
| First.Last@chromasports.com | 50% |
Technology, Information and InternetEngland, United Kingdom51-200 Employees
Chroma design, build and manage digital sports products unparalleled in user experience and engagement. Our clients include sports rights holders, media companies, brands and bookmakers across the globe. We're based in London, Brighton and Sydney.
Company Overview
Media & News
Funding & FinancialsChroma's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsChroma's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com